Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 |
| clinicaltrials |
| NCT04013854 | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | active not recruiting | Phase 2 | 67 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07287917 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | Aminex Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | active not recruiting | Phase 3 | 257 | PfizerINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT07400302 | Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery | recruiting | Phase 2 | 220 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07552597 | Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma: MagMen-II(MagMen-II) | not yet recruiting | Phase 3 | 254 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07803562 | Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp(LODEXA) | not yet recruiting | Phase 2 | 34 | University of California, San DiegoOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | active not recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05089370 | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | active not recruiting | Phase 1 / Phase 2 | 8 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05837767 | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06284590 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients(INTACT/MeRCI) | recruiting | Phase 2 | 162 | Philogen S.p.A.INDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT04557956 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | active not recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04866680 | Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)(PERCIMEL) | active not recruiting | N/A | 136 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer(SONATA) | active not recruiting | N/A | 180 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | recruiting | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07310784 | A Phase II Trial of LM103 in Advanced Melanoma | recruiting | Phase 2 | 92 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07794501 | Markers of Efficacy to Immunotherapy in Patients With Metastatic Melanoma(PREMIO) | not yet recruiting | — | 200 | European Institute of OncologyOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT00923026 | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | enrolling by invitation | — | 1,150 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | active not recruiting | Phase 3 | 267 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | active not recruiting | Phase 2 / Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,301 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT06683755 | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04318717 | Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma | recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06739226 | Combination Immunotherapy Targeting Melanoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05053230 | A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer(IMPROVE) | active not recruiting | N/A | 324 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05625399 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma(RELATIVITY-127) | active not recruiting | Phase 3 | 579 | Bristol-Myers SquibbINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT06598137 | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy | active not recruiting | — | 645 | LMU KlinikumOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07349303 | Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma(NEOPRIME) | recruiting | Phase 2 | 30 | Vastra Gotaland RegionOTHER_GOV | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788729 | Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons(PRISMA) | recruiting | N/A | 384 | University of RegensburgOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06545682 | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | recruiting | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02858921 | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma(Neo Trio) | active not recruiting | Phase 2 | 60 | Melanoma Institute AustraliaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05034536 | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | active not recruiting | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07475572 | Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | recruiting | Phase 1 | 120 | Alvotech Swiss AGINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | recruiting | Phase 2 | 90 | NYU Langone HealthOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01772771 | Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program | recruiting | — | 12,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07524114 | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)(SHERLOCK) | recruiting | — | 7,000 | University Health Network, TorontoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT01644591 | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases | active not recruiting | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02621021 | A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials